(Q38211107)

31 August 2017

NMDA antagonists under investigation for the treatment of major depressive disorder (English)

1 reference

Agnieszka Pałucha-Poniewiera

31 August 2017

corrigendum / erratum

Erratum

0 references

author

Agnieszka Pałucha-Poniewiera

2

0 references

Bernadeta Szewczyk

Bernadeta Szewczyk

3

0 references

Gabriel Nowak

Gabriel Nowak

5

0 references

Andrzej Pilc

4

Andrzej Pilc

1 reference

31 August 2017

1

Bartłomiej Pochwat

1 reference

31 August 2017

language of work or name

English

0 references

publication date

12 May 2014

1 reference

Expert Opinion on Investigational Drugs

31 August 2017

1 reference

31 August 2017

23

1 reference

31 August 2017

9

1 reference

31 August 2017

1181-1192

1 reference

The size and burden of mental disorders and other disorders of the brain in Europe 2010.

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Diagnosis and definition of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Antidepressants for the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Investigational NMDA receptor modulators for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Glutamate-based antidepressants: preclinical psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Molecular diversity of glutamate receptors and implications for brain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Regulation of NMDA receptor Ca2+ signalling and synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

NMDA receptor subunits: diversity, development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

NMDA receptor function: subunit composition versus spatial distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Glutamate-based antidepressants: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Ketamine for depression: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

On the safety and benefits of repeated intravenous injections of ketamine for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Signaling pathways underlying the rapid antidepressant actions of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Ketamine regulates the presynaptic release machinery in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Chronic antidepressants induce redistribution and differential activation of alphaCaM kinase II between presynaptic compartments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Ketamine, magnesium and major depression--from pharmacology to pathophysiology and back

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Glycine site N-methyl-D-aspartate receptor antagonist 7-CTKA produces rapid antidepressant-like effects in male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

A pivotal role of GSK-3 in synaptic plasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Differential trafficking of AMPA receptors following activation of NMDA receptors and mGluRs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

NMDA receptor-mediated PIP5K activation to produce PI(4,5)P₂ is essential for AMPA receptor endocytosis during LTD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Riluzole increases glutamate uptake by cultured C6 astroglial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Brain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Lamotrigine treatment reverses depressive-like behavior and alters BDNF levels in the brains of maternally deprived adult rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

An open-label trial of riluzole in patients with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.918951

10.1517/13543784.2014.918951

21 January 2018

Identifiers

DOI

1 reference

release_a5euslyqyvgohb4wmasualu6fy

31 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a5euslyqyvgohb4wmasualu6fy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference